Correction of Myopia after Cataract Surgery with a Light-Adjustable Lens
Received 30 May 2008; received in revised form 14 January 2009; accepted 11 February 2009. published online 04 June 2009.
Purpose
To determine whether residual myopia could be corrected postoperatively using the light-adjustable lens (LAL) technology in patients undergoing cataract surgery and LAL implantation.
Design
A prospective clinical study was conducted at Codet Vision Institute in Tijuana, Mexico. The LALs were implanted that would purposely result in myopic errors of up to −1.5 D (diopter). The LAL was treated with a spatial intensity profile delivered by a digital light delivery device to induce a targeted myopic refractive change. Once the desirable myopic correction was achieved, the LAL was treated again to lock-in the lens power.
Participants
Fourteen eyes of 14 patients were studied.
Methods
The manifest refraction, uncorrected visual acuity (UCVA), and best- or spectacle-corrected visual acuity (BCVA), were measured with follow up time of 1 to 9 months to determine the achieved refractive corrections and their stability.
Main Outcome Measures
We measured UCVA and BCVA, achieved versus targeted refractive outcome, and refractive stability with follow up time of 1 to 9 months.
Results
Of 14 eyes, 13 eyes (92.9%) achieved 0.25 D of the target refraction at 1 day post lock-in with 100% of the eyes achieving the targeted refractive adjustment within 0.5 D or better with up to 9 months postoperative follow-up. All eyes treated show no change in manifest spherical refraction >0.25 D between 1 day post lock-in, and 3, 6, and 9 months postoperative visits. The data demonstrate the stability of the achieved refractive change after the adjustment and lock-in procedures. The mean rate of change was 0.006 D per month, which is 6 times more stable than that of laser corneal refractive procedures.
Conclusions
Residual myopia errors up to −1.5 D were successfully corrected with precision and significant improvement in UCVA and without compromising BCVA using the LAL technology.
Financial Disclosure(s)
Proprietary or commercial disclosure may be found after the references.
4California Institute of Technology, Pasadena, California
5University of California at San Francisco, San Francisco, California
Correspondence: Arturo Chayet, MD, Ave. Padre Kino No. 10159, Tijuana, Mexico 22320
Manuscript no.: 2008-663.
Financial Disclosure(s): The authors (CS, SC, BT) are Calhoun Vision employees. PR is a former Calhoun Vision employee. AC is the clinical investigator for Calhoun Vision, compensated only for his typical surgery fee for each patient, with no financial interest. DS and RG are both Founding Scientists and a Board Member of Calhoun Vision with financial interest.
ABSTRACT